Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...

Minneapolis - Latinos are the largest racial and ethnic group in the United States, and they comprise two-thirds of Americans with limited English proficiency (LEP). Language and Latino subgroup data ...

New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...

On the heels of a phase 3 win that failed to impress investors, Ironwood Pharmaceuticals is back with more data in efforts to prove that its long-acting GLP-2 analog can do more than beat placebo. The ...

Novartis in August published findings from the phase 3 Cantos trial of Ilaris that weren't "fully compelling to payers," the company's CEO-to-be, Vas Narasimhan, said on a Monday conference call. Now, ...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 – CABOMETYX ...

WASHINGTON, DC—Despite an initial hint to the contrary, Black patients with uncontrolled hypertension seem to benefit from renal denervation to the same extent as non-Black patients by 3 years, ...

FDA advisers elected to not recommend Cytokinetics' heart failure med, voting eight to three that the risks of omecamtiv mecarbil outweigh its potential benefits. The decision pours cold water on a ...

FLORENCE, Italy, June 8, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned ...